Yuyan Pharmaceutical
誉颜制药
Yuyan Pharmaceutical is a drug development subsidiary of Guangzhou-based Yinming Biotech (因明生物), focused on recombinant botulinum toxin. Its flagship asset is YY001, a recombinant type-A botulinum toxin that became the first globally to enter regulatory review in this category when its marketing application for moderate-to-severe glabellar lines was accepted by China's NMPA in December 2024 . The candidate had already completed Phase III trials successfully earlier that year , and the company is also pursuing a medical indication for adult upper-limb muscle spasticity, with that trial approved in July 2024 . Yinming Biotech itself raised a nearly $60 million Series A round in 2021, as noted in Gaorong Venture Capital's portfolio coverage .
AI-generated — may contain errors, please verify.
Coverage
Gaorong Report · 2025 | Innovative Drugs, Agri-Tech, AI Content Platforms Close Funding Rounds; Gaorong Earns Multiple Accolades
Innovation as the sail, hard work as the oar.
Rongbao | Power Semiconductor, Robotics Firms "Steer" Tech Upgrades, AI Applications Make Major Debuts
The Meaning of "Exploration"
Rongbao | Generative AI Powers Industries, Snack Chains Hit 10,000 Stores, Chip Tape-Out Success, Healthcare Goes Global
Innovation lights the path to growth.
Rongbao | Major Acquisition in Innovative Drugs; Laser Chips, Quantum Computing, and Global Payment Platform Secure New Funding
"Every step forward feels like a bloom."
New drug development, energy storage, computing, and semiconductors see breakthrough innovations: homegrown R&D, world-first technologies, and AI-driven advances
Constantly creating new possibilities.
Multiple cutting-edge technologies lead globally — 3D interaction, LiDAR, chips, and medical innovation continue apace | Rongbao · March
Keep learning and evolving through the long cycle of sustained innovation.
